Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. more
Time Frame | SONN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.45% | -3.13% | -0.02% |
1-Month Return | -42.12% | -4.8% | 1.48% |
3-Month Return | -70.72% | -8.46% | 9.63% |
6-Month Return | -87.23% | -2.88% | 13.17% |
1-Year Return | -83.52% | 6.92% | 31.56% |
3-Year Return | -99.85% | 4.63% | 30.19% |
5-Year Return | -99.99% | 42.11% | 93.4% |
10-Year Return | -100% | 103.49% | 198.28% |
Dec '19 | Sep '20 | Sep '21 | Sep '22 | Sep '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 40.61M | - | 483.63K | 349.94K | 147.81K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":1.19,"profit":true},{"date":"2022-09-30","value":0.86,"profit":true},{"date":"2023-09-30","value":0.36,"profit":true}] |
Cost of Revenue | 7.93M | 58.31K | 16.63M | 93.26K | 11.81M | [{"date":"2019-12-31","value":47.69,"profit":true},{"date":"2020-09-30","value":0.35,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":0.56,"profit":true},{"date":"2023-09-30","value":71.02,"profit":true}] |
Gross Profit | 32.68M | (58.31K) | (16.15M) | 256.69K | (11.67M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-09-30","value":-0.18,"profit":false},{"date":"2021-09-30","value":-49.42,"profit":false},{"date":"2022-09-30","value":0.79,"profit":true},{"date":"2023-09-30","value":-35.7,"profit":false}] |
Gross Margin | 80.47% | - | (3339.55%) | 73.35% | (7893.43%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":-4150.24,"profit":false},{"date":"2022-09-30","value":91.16,"profit":true},{"date":"2023-09-30","value":-9809.6,"profit":false}] |
Operating Expenses | 4.71M | 17.41M | 25.57M | 30.02M | 18.94M | [{"date":"2019-12-31","value":15.68,"profit":true},{"date":"2020-09-30","value":58,"profit":true},{"date":"2021-09-30","value":85.18,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":63.09,"profit":true}] |
Operating Income | (4.71M) | (24.24M) | (25.09M) | (29.67M) | (18.79M) | [{"date":"2019-12-31","value":-470833800,"profit":false},{"date":"2020-09-30","value":-2423777200,"profit":false},{"date":"2021-09-30","value":-2508743600,"profit":false},{"date":"2022-09-30","value":-2966935900,"profit":false},{"date":"2023-09-30","value":-1879261700,"profit":false}] |
Total Non-Operating Income/Expense | (325.75K) | (6.67K) | 103.49K | (52.48K) | - | [{"date":"2019-12-31","value":-314.76,"profit":false},{"date":"2020-09-30","value":-6.44,"profit":false},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":-50.71,"profit":false},{"date":"2023-09-30","value":"-","profit":true}] |
Pre-Tax Income | (4.87M) | (24.27M) | (24.98M) | (29.72M) | (18.83M) | [{"date":"2019-12-31","value":-487121100,"profit":false},{"date":"2020-09-30","value":-2426511500,"profit":false},{"date":"2021-09-30","value":-2498396100,"profit":false},{"date":"2022-09-30","value":-2972184100,"profit":false},{"date":"2023-09-30","value":-1883269400,"profit":false}] |
Income Taxes | 162.87K | 6.80M | 22.03K | 52.48K | 40.08K | [{"date":"2019-12-31","value":2.4,"profit":true},{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":0.32,"profit":true},{"date":"2022-09-30","value":0.77,"profit":true},{"date":"2023-09-30","value":0.59,"profit":true}] |
Income After Taxes | (5.03M) | (31.06M) | (25.01M) | (29.77M) | - | [{"date":"2019-12-31","value":-503408400,"profit":false},{"date":"2020-09-30","value":-3106064000,"profit":false},{"date":"2021-09-30","value":-2500598700,"profit":false},{"date":"2022-09-30","value":-2977432300,"profit":false},{"date":"2023-09-30","value":"-","profit":true}] |
Income From Continuous Operations | (17.44M) | (24.27M) | (24.98M) | (29.72M) | (18.83M) | [{"date":"2019-12-31","value":-1744335800,"profit":false},{"date":"2020-09-30","value":-2426511500,"profit":false},{"date":"2021-09-30","value":-2498396100,"profit":false},{"date":"2022-09-30","value":-2972184100,"profit":false},{"date":"2023-09-30","value":-1883269400,"profit":false}] |
Income From Discontinued Operations | (1.02M) | - | - | - | - | [{"date":"2019-12-31","value":-102167400,"profit":false},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Net Income | (5.03M) | (31.06M) | (25.01M) | (29.77M) | (18.83M) | [{"date":"2019-12-31","value":-503408400,"profit":false},{"date":"2020-09-30","value":-3106064000,"profit":false},{"date":"2021-09-30","value":-2500598700,"profit":false},{"date":"2022-09-30","value":-2977432300,"profit":false},{"date":"2023-09-30","value":-1883269400,"profit":false}] |
EPS (Diluted) | - | (5.58) | (3.43) | (6.85) | (3.36) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-09-30","value":-557.65,"profit":false},{"date":"2021-09-30","value":-343,"profit":false},{"date":"2022-09-30","value":-685,"profit":false},{"date":"2023-09-30","value":-336,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SONN | |
---|---|
Cash Ratio | 1.14 |
Current Ratio | 1.65 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SONN | |
---|---|
ROA (LTM) | -96.93% |
ROE (LTM) | -264.57% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SONN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.55 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.45 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SONN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 29.68 |
P/B | 0.63 |
Price/FCF | NM |
EV/R | 35.91 |
EV/Ebitda | NM |
Sonnet Biotherapeutics Holdings Inc (SONN) share price today is $1.78
Yes, Indians can buy shares of Sonnet Biotherapeutics Holdings Inc (SONN) on Vested. To buy Sonnet Biotherapeutics Holdings Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SONN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Sonnet Biotherapeutics Holdings Inc (SONN) via the Vested app. You can start investing in Sonnet Biotherapeutics Holdings Inc (SONN) with a minimum investment of $1.
You can invest in shares of Sonnet Biotherapeutics Holdings Inc (SONN) via Vested in three simple steps:
The 52-week high price of Sonnet Biotherapeutics Holdings Inc (SONN) is $18.72. The 52-week low price of Sonnet Biotherapeutics Holdings Inc (SONN) is $1.66.
The price-to-earnings (P/E) ratio of Sonnet Biotherapeutics Holdings Inc (SONN) is
The price-to-book (P/B) ratio of Sonnet Biotherapeutics Holdings Inc (SONN) is 0.63
The dividend yield of Sonnet Biotherapeutics Holdings Inc (SONN) is 0.00%
The market capitalization of Sonnet Biotherapeutics Holdings Inc (SONN) is $1.66M
The stock symbol (or ticker) of Sonnet Biotherapeutics Holdings Inc is SONN